Back to top

rating-upgrade: Archive

Zacks Equity Research

Adaptive Biotechnologies (ADPT) Moves to Buy: Rationale Behind the Upgrade

Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ADPTPositive Net Change

Zacks Equity Research

Banco Macro (BMA) Upgraded to Strong Buy: What Does It Mean for the Stock?

Banco Macro (BMA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

BMANegative Net Change

Zacks Equity Research

New Gold (NGD) Upgraded to Buy: Here's What You Should Know

New Gold (NGD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

NGDPositive Net Change

Zacks Equity Research

California BanCorp (BCAL) Upgraded to Strong Buy: Here's Why

California BanCorp (BCAL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

BCALPositive Net Change

Zacks Equity Research

GameStop (GME) Upgraded to Buy: What Does It Mean for the Stock?

GameStop (GME) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GMENegative Net Change

Zacks Equity Research

What Makes Xenia Hotels & Resorts (XHR) a New Buy Stock

Xenia Hotels & Resorts (XHR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

XHRPositive Net Change

Zacks Equity Research

All You Need to Know About Freshpet (FRPT) Rating Upgrade to Buy

Freshpet (FRPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

FRPTPositive Net Change

Zacks Equity Research

OMV (OMVKY) Moves to Strong Buy: Rationale Behind the Upgrade

OMV (OMVKY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

OMVKYPositive Net Change

Zacks Equity Research

What Makes Sony (SONY) a New Buy Stock

Sony (SONY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

SONYNegative Net Change

Zacks Equity Research

Victoria's Secret (VSCO) Upgraded to Buy: Here's What You Should Know

Victoria's Secret (VSCO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

VSCONegative Net Change

Zacks Equity Research

Peloton (PTON) Upgraded to Buy: Here's Why

Peloton (PTON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PTONPositive Net Change

Zacks Equity Research

Suncor Energy (SU) Upgraded to Buy: Here's What You Should Know

Suncor Energy (SU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

SUNegative Net Change

Zacks Equity Research

What Makes Reservoir Media (RSVR) a New Buy Stock

Reservoir Media (RSVR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

RSVRPositive Net Change

Zacks Equity Research

Barclays (BCS) Upgraded to Buy: Here's What You Should Know

Barclays (BCS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BCSNegative Net Change

Zacks Equity Research

Construction Partners (ROAD) Upgraded to Buy: What Does It Mean for the Stock?

Construction Partners (ROAD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ROADPositive Net Change

Zacks Equity Research

Ezcorp (EZPW) Upgraded to Strong Buy: Here's What You Should Know

Ezcorp (EZPW) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

EZPWPositive Net Change

Zacks Equity Research

Fulton Financial (FULT) Upgraded to Buy: What Does It Mean for the Stock?

Fulton Financial (FULT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

FULTPositive Net Change

Zacks Equity Research

All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy

IDEAYA Biosciences (IDYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

IDYAPositive Net Change

Zacks Equity Research

Alerus (ALRS) Upgraded to Buy: Here's What You Should Know

Alerus (ALRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ALRSPositive Net Change

Zacks Equity Research

Premier (PINC) Upgraded to Strong Buy: Here's What You Should Know

Premier (PINC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

PINCPositive Net Change

Zacks Equity Research

Equillium (EQ) Upgraded to Buy: Here's What You Should Know

Equillium (EQ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

EQNegative Net Change

Zacks Equity Research

Byrna Technologies (BYRN) Upgraded to Strong Buy: Here's What You Should Know

Byrna Technologies (BYRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

BYRNNegative Net Change

Zacks Equity Research

All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy

Rapt Therapeutics (RAPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

RAPTPositive Net Change

Zacks Equity Research

What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock

Kyverna Therapeutics, Inc. (KYTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

KYTXNegative Net Change

Zacks Equity Research

Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: What Does It Mean for the Stock?

Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CMPXPositive Net Change